Activity of 2 methoxyestradiol (Panzem® NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial

Gynecologic Oncology

Volumn 115, Issue 1, 2009, Pages 90-96

  Matei, Daniela ^a,b,f   Schilder, Jeanne ^a,f   Sutton, Gregory ^c,f   Perkins, Susan ^a,f   Breen, Tim ^a,f   Quon, Check ^d,f   Sidor, Carolyn ^e,f  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Bren Cancer Center ^*  (United States)

^d iNDa Consulting Inc   (United States)

^e ENTREMED INC   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 methoxyestradiol; Angiogenesis; Clinical trial; Ovarian cancer

Indexed keywords

2 METHOXYESTRADIOL; 2 METHOXYESTRONE; BETA TUBULIN; CA 125 ANTIGEN; CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NANOCRYSTAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATINUM DERIVATIVE; PROTEIN KINASE B; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ARTICLE; CANCER RELAPSE; CANCER RESISTANCE; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; CONSTIPATION; COUGHING; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER FUNCTION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OPEN STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; FEMALE; HUMANS; HYDROXYESTRONES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 69249212263     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.05.042     Document Type: Article

References (59)

1. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 2000. CA Cancer J. Clin. 50 (2000) 7-33
2. Ozols R., Schwartz P.E., and Eifel P.J. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. In: Hellman S., Rosenberg S., and DeVita V.T. (Eds). Cancer, Principles and Practice of Oncology vol. 1 (1997), Lippincott-Raven, Philadelphia, New York 1502-1540
3. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19 (2001) 3312-3322
4. Bookman M.A., Darcy K.M., Clarke-Pearson D., Boothby R.A., and Horowitz R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21 (2003) 283-290
5. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29 (2002) 15-18
6. Liotta L.A., Steeg P.S., and Stetler-Stevenson W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64 (1991) 327-336
7. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrinol. Rev. (1997) 4-25
8. Gadducci A., Viacava P., Cosio S., Fanelli G., Fanucchi A., Cecchetti D., et al. Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. Anticancer Res. 23 (2003) 549-556
9. Stone P.J., Goodheart M.J., Rose S.L., Smith B.J., DeYoung B.R., and Buller R.E. The influence of microvessel density on ovarian carcinogenesis. Gynecol. Oncol. 90 (2003) 566-571
10. Gadducci A., Ferdeghini M., Fanucchi A., Annicchiarico C., Ciampi B., Prontera C., and Genazzani A.R. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res. 19 (1999) 1401-1405
11. Ghosh S., and Maity P. Isolation and purification of vascular endothelial growth factor (VEGF) from ascitic fluid of ovarian cancer patients. Pathol. Oncol. Res. 10 (2004) 104-108
12. Li L., Wang L., Zhang W., Tang B., Zhang J., Song H., et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 24 (2004) 1973-1979
13. Obermair A., Tempfer C., Hefler L., Preyer O., Kaider A., Zeillinger R., et al. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. Br. J. Cancer 77 (1998) 1870-1874
14. Wong C., Wellman T.L., and Lounsbury K.M. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol. Oncol. 91 (2003) 513-517
15. Hata K., Udagawa J., Fujiwaki R., Nakayama K., Otani H., and Miyazaki K. Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer. Oncology 62 (2002) 340-348
16. Zhang L., Yang N., Park J.W., Katsaros D., Fracchioli S., Cao G., et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res. 63 (2003) 3403-3412
17. Afzal S., Lalani E.N., Poulsom R., Stubbs A., Rowlinson G., Sato H., et al. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum. Pathol. 29 (1998) 155-165
18. Garzetti G.G., Ciavattini A., Lucarini G., Goteri G., de e Nictolis M., Garbisa S., et al. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Anticancer Res. 15 (1995) 2799-2804
19. Burger RA, MS, Monk BJ, Greer B, Sorosky J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study Proc of American Soc of Clinical Oncology, 2005.
20. Garcia AA, AMO, Hirte H, Fleming G, Tsao-Wei D, Roman L, et al. Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: a California Cancer Consortium Trial Proc of American Soc of Clinical Oncology, 2005.
21. Hughes R.A., Harris T., Altmann E., McAllister D., Vlahos R., Robertson A., et al. 2-Methoxyestradiol and analogs as novel antiproliferative agents: analysis of three-dimensional quantitative structure-activity relationships for DNA synthesis inhibition and estrogen receptor binding. Mol. Pharmacol. 61 (2002) 1053-1069
22. Fotsis T., Zhang Y., Pepper M.S., Adlercreutz H., Montesano R., Nawroth P.P., and Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368 (1994) 237-239
23. Becker C.M., Rohwer N., Funakoshi T., Cramer T., Bernhardt W., Birsner A., et al. 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am. J. Pathol. 172 (2008) 534-544
24. Ricker J.L., Chen Z., Yang X.P., Pribluda V.S., Swartz G.M., and Van Waes C. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin. Cancer Res. 10 (2004) 8665-8673
25. Cushman M., He H.M., Katzenellenbogen J.A., Lin C.M., and Hamel E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J. Med. Chem. 38 (1995) 2041-2049
26. Kamath K., Okouneva T., Larson G., Panda D., Wilson L., and Jordan M. A. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol. Cancer Ther. 5 (2006) 2225-2233
27. Shimada K., Nakamura M., Ishida E., Kishi M., and Konishi N. Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 24 (2003) 1067-1075
28. Kumar A.P., Garcia G.E., and Slaga T.J. 2-methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells. Mol. Carcinog. 31 (2001) 111-124
29. Perez-Stable C. 2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells. Cancer Lett. 231 (2006) 49-64
30. Lin H.L., Liu T.Y., Chau G.Y., Lui W.Y., and Chi C.W. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 89 (2000) 983-994
31. LaVallee T.M., Zhan X.H., Johnson M.S., Herbstritt C.J., Swartz G., Williams M.S., et al. S. 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res. 63 (2003) 468-475
32. Han G.Z., Liu Z.J., Shimoi K., and Zhu B.T. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res. 65 (2005) 387-393
33. Schumacher G., Kataoka M., Roth J.A., and Mukhopadhyay T. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin. Cancer Res. 5 (1999) 493-499
34. Sweeney C., Liu G., Yiannoutsos C., Kolesar J., Horvath D., Staab M.J., et al. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin. Cancer Res. 11 (2005) 6625-6633
35. Dahut W.L., Lakhani N.J., Gulley J.L., Arlen P.M., Kohn E.C., Kotz H., et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol. Ther. 5 (2006) 22-27
36. James J., Murry D.J., Treston A.M., Storniolo A.M., Sledge G.W., Sidor C., and Miller K.D. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest. New Drugs 25 (2007) 41-48
37. Fogler WE, VK, Swartz GM, Plum SM, Strawn SJ, LaVallee TM, et al. The antitumor activity of 2-methoxyestradiol is maximized by maintaining a threshold concentration over a 24-hour dosing interval. . Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, B180, page 173.
38. ® NCD in a murine orthotopic lung cancer model. AACR Proceedings 703 (2005) Abstract
39. Liu G., QC, Sidor C., Feierabend C., and Eun J. Wilding G Phase Ib trial of 2ME2 administered as a nannocrystal dispersion (NCD) in patients with advanced cancer. Proceedings of EORTC/AACR/NCI B14 (2005) 129
40. Sweeney C., PJ, Slebe K., Li M., Quon C., Treston A., and Sidor C. A single center, open label, dose escalation, safety and pharmacokinetic study of 2 methoxi-nannocrystal colloidal dispersion administered orally to patients with advanced cancer. Proceedings of AACR-EORTC-NCI B121 (2005) 157
41. Klauber N., Parangi S., Flynn E., Hamel E., and D'Amato R.J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57 (1997) 81-86
42. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
43. Rustin G.J. Use of CA-125 to assess response to new agents in ovarian cancer trials. J. Clin. Oncol. 21 (2003) 187-193
44. Cheng J.Q., Jiang X., Fraser M., Li M., Dan H.C., Sun M., and Tsang B.K. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist. Updat. 5 (2002) 131-146
45. Mabjeesh N.J., Escuin D., LaVallee T.M., Pribluda V.S., Swartz G.M., Johnson M.S., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003) 363-375
46. Klauber N., Parangi S., Flynn E., Hamel E., and D'Amato R.J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57 (1997) 81-86
47. Lippert T.H., Adlercreutz H., Berger M.R., Seeger H., Elger W., and Mueck A.O. Effect of 2-methoxyestradiol on the growth of methyl-nitroso-urea (MNU)-induced rat mammary carcinoma. J. Steroid. Biochem. Mol. Biol. 84 (2003) 51-56
48. Banerjeei S.K., Zoubine M.N., Sarkar D.K., Weston A.P., Shah J.H., and Campbell D.R. 2-methoxyestradiol blocks estrogen-induced rat pituitary tumor growth and tumor angiogenesis: possible role of vascular endothelial growth factor. Anticancer Res. 20 (2000) 2641-2645
49. Schilder R.J., Sill M.W., Chen X., Darcy K.M., Decesare S.L., Lewandowski G., et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin. Cancer Res. 11 (2005) 5539-5548
50. Seve P., Reiman T., Lai R., Hanson J., Santos C., Johnson L., et al. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother. Pharmacol. 60 (2007) 27-34
51. Dumontet C., Isaac S., Souquet P.J., Bejui-Thivolet F., Pacheco Y., Peloux N., et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull. Cancer 92 (2005) E25-E30
52. Dumontet C., and Sikic B.I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 17 (1999) 1061-1070
53. Seve P., Mackey J., Isaac S., Tredan O., Souquet P.J., Perol M., et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol. Cancer Ther. 4 (2005) 2001-2007
54. Seve P., Isaac S., Tredan O., Souquet P.J., Pacheco Y., Perol M., et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin. Cancer Res. 11 (2005) 5481-5486
55. Gokmen-Polar Y., Escuin D., Walls C.D., Soule S.E., Wang Y., Sanders K.L., et al. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Res. 65 (2005) 9406-9414
56. Liaw T.Y., Salam N.K., McKay M.J., Cunningham A.M., Hibbs D.E., and Kavallaris M. Class I {beta}-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions. Mol. Cancer Ther. 7 (2008) 3150-3159
57. Moser C., Lang S.A., Mori A., Hellerbrand C., Schlitt H.J., Geissler E.K., et al. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer 8 (2008) 206
58. Fernandes T.G., Kwon S.J., Lee M.Y., Clark D.S., Cabral J.M., and Dordick J.S. On-chip, cell-based microarray immunofluorescence assay for high-throughput analysis of target proteins. Anal. Chem. 80 (2008) 6633-6639
59. LaVallee T.M., Burke P.A., Swartz G.M., Hamel E., Agoston G.E., Shah J., et al. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol. Cancer Ther. 7 (2008) 1472-1482